Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL358779 | 0.83 | RXFP1 (0.44) | RXFP1KDM4ABRD9KAT6ALMNA | |
| SCHEMBL30048786 | 0.82 | RXFP1 (0.43) | RXFP1KDM4ABRD9KAT6ALMNA | |
| SCHEMBL29353000 | 0.81 | HDAC1 (0.52) | RXFP1BRD9LMNAPOLBHDAC1 | |
| SCHEMBL211033 | 0.81 | HDAC1 (0.52) | RXFP1BRD9LMNAPOLBHDAC1 | |
| SCHEMBL5194657 | 0.81 | PTPN1 (0.59) | RXFP1KDM4ABRD9KAT6AIDO1 | |
| SCHEMBL4212736 | 0.80 | CA12 (0.41) | RXFP1BRD9AAK1 | |
| SCHEMBL28734163 | 0.79 | KDM4E (0.48) | RXFP1KDM4AMEN1NPC1GAA | |
| SCHEMBL29679253 | 0.79 | KDM4E (0.48) | RXFP1KDM4AMEN1NPC1GAA | |
| SCHEMBL3790650 | 0.78 | HDAC2 (0.65) | HDAC1HDAC3HDAC2 | |
| SCHEMBL5868802 | 0.78 | ABCB1 (0.54) | BRD9AAK1HDAC1CNR2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546358-B2 | Method of treating asthma | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-01 | — | — | US | disclosed |
| US-8546358-B2 | Method of treating asthma | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-01 | — | — | US | disclosed |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | HAWKINS MICHAEL J (US) | 2012-01-26 | — | — | US | disclosed |
| US-20100048513-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2010-02-25 | — | — | US | disclosed |
| US-7645785-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-2038259-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-20090036409-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2009-02-05 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
| US-20080021027-A1 | Novel benzimidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-24 | — | — | US | disclosed |
| WO-2008000643-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
| WO-2005073214-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048513-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | RXFP1 2591/4885KDM4A 2510/4885BRD9 2697/4885 |
| US-20090036409-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | RXFP1 2591/4885KDM4A 2510/4885BRD9 2697/4885 |
| US-20080021027-A1 | Novel benzimidazole derivatives | NR1H4, GPR119, GLP1R | RXFP1 99/4885KDM4A 2922/4885BRD9 664/4885 |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | CMA1, SERPINB1, TPSAB1 | RXFP1 2591/4885KDM4A 2510/4885BRD9 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.